✦ LIBER ✦

OR7-8: A phase II randomised, open-label, parallelgroup study of the safety, tolerability, pharmacokinetics and efficacy of two subcutaneous dosing regimens of ATL1103 in adult patients with acromegaly

✍ Scribed by Trainer, P.J.; Newell-Price, J.; Ayuk, J.; Aylwin, S.; Drake, W.M.; Rees, A.; Chanson, P.; Brue, T.; Webb, S.M.; Fajardo, C.; Aller, J.; McCormack, A.; Torpy, D.J.; Tachas, G.; Atley, L.M.; Bidlingmaier, M.

Book ID: 126760332
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 449 KB
Volume: 24
Category: Article
ISSN: 1096-6374
DOI: 10.1016/S1096-6374(14)50054-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicenter open-label phase I/II stud

A multicenter open-label phase I/II study to assess the safety, tolerability, and efficacy of three dose levels of TuNEX in patients with rheumatoid arthritis

✍ Der-Yuan Chen; Ning-Sheng Lai; Ling-Ying Lu; Hsiu-Cheng Chou; Yi-Hsing Chen; Tsu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 Chinese ⚖ 428 KB

OR03-5 A phase 2, multicenter, multiple-

OR03-5 A phase 2, multicenter, multiple-dose, open-label, parallel-group, active controlled, safety, tolerability, pharmacokinetic and pharmacodynamic study of ACP-001 in adult patients with Growth Hormone Deficiency (AGHD)

✍ Höybye, C.; Pfeiffer, A.F.H.; Ferone, D.; Gilfoyle, D.; Beckert, M.; Christianse 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Prospective, multicenter, randomized, in

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

✍ Heigener, David F.; von Pawel, Joachim; Eschbach, Corinna; Brune, Andreas; Schmi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 316 KB